Focus: Blue Earth Diagnostics is a UK-based molecular imaging company specializing in positron emission tomography (PET) radiopharmaceuticals for oncology, neurology, and cardiovascular disease detection. The company operates at commercial scale with two FDA-approved products and a robust pipeline spanning multiple cancer and neurological indications.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Hot — 337 jobs added in 30d
Net +300 (337 new, 37 removed). Aggressive expansion phase.
Best fit for commercial, clinical development, and medical affairs professionals seeking stable growth in a niche diagnostic imaging company; less suitable for scientists seeking cutting-edge R&D or clear innovation narratives.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead marketed product with 15-year patent runway; prostate cancer imaging for patient stratification and surveillance.
Help build intelligence for Blue Earth Diagnostics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Blue Earth Diagnostics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Established oncology imaging agent with extended patent protection; core revenue driver for commercial organization.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo